Blood & Lymphoreticular

Monoclonal gammopathy of undetermined significance

Clinical Overview and When to Suspect MGUS

— Serum monoclonal (M) protein <3 g/dL

— Clonal bone marrow plasma cells <10%

— Absence of CRAB features (hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) and no myeloma-defining events (no ≥60% plasma cells, no involved/uninvolved free light chain ratio ≥100, no >1 focal MRI lesion)

— No amyloidosis or other related disorder explaining symptoms

— Prevalence ~3% in patients >50, ~5% >70, ~7–8% >85

— More common in men, Black patients (2–3× higher), first-degree relatives of myeloma patients

— Risk of progression to multiple myeloma, Waldenström macroglobulinemia, AL amyloidosis, or lymphoma is ~1% per year, lifelong and non-diminishing

— Incidental finding on serum protein electrophoresis (SPEP) ordered for another reason (elevated total protein, unexplained anemia workup, neuropathy, osteoporosis, recurrent infections, elevated ESR)

— Asymptomatic older adult with mildly elevated globulin fraction (gamma gap = total protein – albumin >4 g/dL)

— Patient with peripheral neuropathy of unclear etiology — check SPEP/IFE/SFLC

— Unexplained renal disease with proteinuria (rule out light-chain related disease, MGRS)

— Non-IgM (IgG, IgA, IgD): ~progresses to multiple myeloma

— IgM MGUS: progresses to Waldenström macroglobulinemia or lymphoma

— Light-chain MGUS: abnormal free light chain ratio, no heavy chain, urine monoclonal light chain <500 mg/24h; progresses to light-chain myeloma or AL amyloidosis

Board pearl: MGUS is a diagnosis of exclusion — you cannot call it MGUS until you have proven there are no CRAB features and no end-organ damage attributable to the clone. Always check CBC, calcium, creatinine, and consider imaging before labeling.

Definition: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell/B-cell disorder defined by:

Epidemiology:

When to suspect MGUS on Step 3:

Three MGUS subtypes:

Presentation Patterns and Key History

— Routine chemistry panel reveals elevated total protein with normal albumin → widened gamma gap

— Workup for fatigue, anemia, back pain, recurrent infections in an older patient

— Evaluation of peripheral neuropathy (especially distal symmetric sensory or sensorimotor), most strongly associated with IgM MGUS and anti-MAG antibodies

— Evaluation of unexplained osteoporosis or fragility fracture in a man or premenopausal woman

— Renal workup: proteinuria, AKI, or nephrotic syndrome → consider MGRS (monoclonal gammopathy of renal significance)

— Bone pain, particularly axial/back/rib — concern for lytic lesions/myeloma

— B symptoms (fevers, drenching sweats, weight loss) — concern for lymphoma/Waldenström

— Hyperviscosity symptoms (blurry vision, headache, mucosal bleeding, confusion) — IgM Waldenström

— Macroglossia, periorbital purpura, carpal tunnel, restrictive cardiomyopathy, nephrotic-range proteinuria — AL amyloidosis

— Recurrent bacterial infections out of proportion to age

— Raynaud, acrocyanosis, cold-induced purpura — cryoglobulinemia

— Family history of MGUS, myeloma, lymphoma (first-degree relatives carry ~2× risk)

— Prior radiation, pesticide/herbicide exposure (Agent Orange — VA presumptive condition for myeloma)

— Race/ethnicity (Black patients have higher prevalence and earlier onset)

— Medication history (avoid bisphosphonate misuse, NSAID nephrotoxicity in setting of clonal disease)

Key distinction: A patient who has the lab profile of MGUS but reports bone pain, hypercalcemia symptoms, or progressive fatigue with anemia is NOT MGUS — proceed to full myeloma workup including marrow biopsy and whole-body imaging before settling on a benign label.

Classic presentation: Asymptomatic, incidental finding — this is the rule, not the exception. The patient feels well; the lab tipped you off.

Common triggering scenarios:

Red-flag symptoms that argue AGAINST simple MGUS (suggest progression or alternative diagnosis):

Pertinent history elements:

Physical Exam Findings

— Vital signs: orthostatics (amyloid autonomic neuropathy, anemia), resting tachycardia (anemia or cardiac amyloid)

— General: pallor (anemia → consider myeloma), cachexia (B-symptoms → lymphoma/Waldenström)

— HEENT: macroglossia with lateral tooth indentations → AL amyloidosis; periorbital "raccoon-eye" purpura after Valsalva → amyloid; retinal findings — sausage-link venous dilation, hemorrhages → IgM hyperviscosity

— Lymph nodes & spleen: lymphadenopathy or splenomegaly → think Waldenström, lymphoma, or CLL with paraprotein, not MGUS

— Cardiac: elevated JVP, S4, signs of restrictive cardiomyopathy → cardiac amyloid

— Abdomen: hepatomegaly (amyloid, Waldenström)

— Musculoskeletal: focal bony tenderness over spine/ribs/long bones → lytic lesion concern; gentle palpation only — avoid percussion that could fracture

— Neurologic: distal symmetric sensory loss, decreased vibration/proprioception, areflexia — peripheral neuropathy (anti-MAG with IgM); carpal tunnel signs (Phalen/Tinel) — amyloid; orthostatic hypotension without compensatory tachycardia — amyloid autonomic involvement

— Skin: waxy thickening, easy bruising, pinch purpura — AL amyloid

— Low-voltage ECG with thick walls on echo (discordance)

— Narrow pulse pressure, orthostasis

— Sensitivity for clinical exam is low; NT-proBNP and troponin are screening tools

Step 3 management: When you find an M-protein, document a focused exam at every annual visit — new lymphadenopathy, hepatosplenomegaly, bone tenderness, neuropathy, or signs of amyloidosis are clinical triggers to re-image and re-stage, not just repeat the SPEP.

Hallmark of MGUS exam: essentially normal. Any positive finding should prompt you to question the diagnosis and look for progression or a related plasma cell dyscrasia.

Targeted exam to perform at diagnosis and on follow-up:

Hemodynamic assessment when amyloid suspected:

Diagnostic Workup — Initial Labs

— SPEP (serum protein electrophoresis): detects and quantifies M-spike

— Serum immunofixation (IFE): identifies heavy and light chain isotype (IgG-κ, IgM-λ, etc.) — more sensitive than SPEP

— Serum free light chain (SFLC) assay: quantifies κ and λ; calculate κ/λ ratio (normal 0.26–1.65)

— 24-hour urine protein with UPEP and urine IFE: detects Bence Jones (monoclonal light chain) proteinuria

— Quantitative immunoglobulins (IgG, IgA, IgM): assess for immunoparesis (suppression of uninvolved isotypes — a risk factor for progression)

— CBC with differential: anemia (Hgb <10 or >2 g/dL below baseline = myeloma-defining)

— CMP: calcium (corrected for albumin >11 or >1 above ULN = myeloma); creatinine/eGFR (<40 mL/min or Cr >2 mg/dL attributable to clone)

— LDH, β2-microglobulin, albumin: baseline prognostic markers (used in ISS staging if myeloma develops)

— Peripheral smear: rouleaux formation supports paraproteinemia; look for circulating plasma cells

— Skeletal survey is outdated; low-dose whole-body CT or whole-body MRI preferred for any patient with suspected myeloma; not routinely required in low-risk MGUS without symptoms

— PET/CT acceptable alternative

— If neuropathy: anti-MAG antibody (IgM), anti-GM1, EMG/NCS

— If renal disease: urine albumin-to-protein ratio (discordance suggests light-chain disease), renal biopsy if MGRS suspected

— If amyloid suspected: NT-proBNP, troponin, fat pad aspirate with Congo red

Board pearl: The gamma gap (total protein − albumin) >4 g/dL on routine chemistry is a cheap, high-yield screen — always trigger SPEP/IFE/SFLC when you see it in an older patient.

Step 1 — Confirm and characterize the paraprotein:

Step 2 — Screen for end-organ damage (rule out CRAB):

Step 3 — Initial bone screening (if indicated):

Additional targeted labs when clinically driven:

Diagnostic Workup — Advanced or Confirmatory Studies

— Required for any of the following ("not low-risk MGUS"):

— M-protein ≥1.5 g/dL

— Non-IgG isotype (IgA, IgM, IgD)

— Abnormal SFLC ratio

— Any CRAB feature, neuropathy of unclear cause, or suspicion of amyloidosis/MGRS

— Mayo "low-risk" MGUS (IgG, M-protein <1.5 g/dL, normal SFLC ratio) → bone marrow biopsy is NOT required if asymptomatic and labs are normal

— Clonal plasma cells <10%

— No sheets of plasma cells, no extensive fibrosis, no significant cytogenetic high-risk markers driving therapy

— Flow cytometry can quantify aberrant clonal/normal plasma cell ratio (>95% aberrant = higher risk)

— FISH for myeloma-associated abnormalities (t(4;14), t(14;16), del(17p), 1q gain) — prognostic if progression occurs

— Whole-body low-dose CT (WBLDCT) or whole-body MRI in intermediate/high-risk MGUS or any bone symptom — detects lytic lesions and focal marrow lesions; >1 focal lesion ≥5 mm on MRI = myeloma-defining event

— PET/CT acceptable; plain skeletal survey is now considered inadequate

— Suspected AL amyloidosis: fat pad aspirate, abdominal fat or affected-organ biopsy with Congo red (apple-green birefringence), mass spectrometry typing (gold standard — distinguishes AL from ATTR and AA)

— Suspected Waldenström: marrow lymphoplasmacytic infiltrate, MYD88 L265P mutation (>90% of WM)

— Suspected MGRS: renal biopsy with immunofluorescence and electron microscopy

— Hyperviscosity: measured serum viscosity (symptoms typically >4 cP)

Key distinction: Smoldering multiple myeloma = M-protein ≥3 g/dL OR marrow plasma cells 10–60%, but still no CRAB and no myeloma-defining events. SMM has a much higher progression rate (~10%/year first 5 years) than MGUS (~1%/year) — different surveillance and counseling.

Bone marrow biopsy — when to do it:

Bone marrow findings expected in MGUS:

Imaging escalation:

Special confirmatory testing:

Risk Stratification and Management Logic

— M-protein ≥1.5 g/dL

— Non-IgG isotype (IgA, IgM, IgD)

— Abnormal serum free light chain ratio (κ/λ outside 0.26–1.65)

— Low risk (0 factors): ~5% — IgG, M <1.5 g/dL, normal SFLC ratio

— Low-intermediate (1 factor): ~21%

— High-intermediate (2 factors): ~37%

— High risk (3 factors): ~58%

— Low-risk MGUS:

— Recheck SPEP, CBC, calcium, creatinine at 6 months

— If stable, follow every 2–3 years or with symptoms; no bone marrow, no imaging

— Intermediate/high-risk MGUS:

— Bone marrow biopsy and whole-body imaging at baseline

— Repeat SPEP, SFLC, CBC, calcium, creatinine at 6 months, then annually for life

— Any new symptoms (bone pain, anemia, renal dysfunction, neuropathy, B-symptoms) → immediate restaging

— Rising M-protein (>25% increase and >0.5 g/dL absolute) → re-evaluate for SMM or myeloma

— New CRAB feature or myeloma-defining event → diagnose multiple myeloma → refer hematology/oncology for therapy

— IgM with lymphadenopathy/marrow infiltrate → Waldenström evaluation

Step 3 management: The single highest-yield outpatient decision is risk-stratify, then schedule the 6-month follow-up labs at the index visit. Document that you counseled the patient on the 1%/year progression risk and the symptoms that should trigger early return.

Mayo Clinic risk stratification model — three adverse risk factors:

Risk categories and 20-year progression risk:

Management is observation only — there is no role for chemotherapy, immunomodulators, or steroids in MGUS itself. Treating MGUS does not prevent progression and exposes patients to harm.

Surveillance schedule (Step 3 high-yield):

When the diagnosis shifts:

Pharmacotherapy — There Is No First-Line Drug for MGUS

— MGUS-associated peripheral neuropathy (IgM, anti-MAG positive):

— Symptomatic care: gabapentin, pregabalin, duloxetine, TCAs

— Severe/progressive: rituximab under neurology/heme co-management

— IVIG is generally ineffective for anti-MAG neuropathy

— POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin changes; usually λ light chain, elevated VEGF):

— Treat with radiation (if single plasmacytoma) or systemic therapy (lenalidomide, autoSCT)

— AL amyloidosis:

— Daratumumab + CyBorD (cyclophosphamide/bortezomib/dexamethasone) is current first-line

— Consider autoSCT in eligible patients

— MGRS:

— Clone-directed therapy even without meeting myeloma criteria — bortezomib-based regimens; renal preservation is the goal

— Cryoglobulinemia (type I, monoclonal):

— Treat underlying clone; plasmapheresis for severe vasculitis

— Cold agglutinin disease (IgM-mediated hemolysis):

— Cold avoidance; rituximab ± bendamustine; sutimlimab (anti-C1s) approved

— Bone health: vitamin D repletion, calcium intake, weight-bearing exercise; DXA if risk factors — treat osteoporosis per usual guidelines (bisphosphonates only if standard indications; not prophylactically for MGUS)

— Vaccinations: annual influenza, pneumococcal (PCV20 or PCV15→PPSV23), RSV (age-appropriate), zoster, COVID-19 — patients with immunoparesis are at higher infection risk

— Avoid nephrotoxins: counsel against routine NSAID use, IV iodinated contrast caution if borderline renal function

Board pearl: A vignette describing a patient with stable MGUS asking "should I start medication to prevent myeloma?" — the correct answer is reassurance and continued surveillance, never empiric therapy.

Core principle: MGUS itself is not treated pharmacologically. Treating asymptomatic clonal disease with myeloma-directed therapy is harmful and not standard of care. The "management" is risk-stratified surveillance.

However, several MGUS-related conditions DO require therapy — recognize and refer:

Supportive measures relevant to all MGUS patients:

Expanded Pharmacology — Adjacent Therapeutics You Must Recognize

— VRd (bortezomib + lenalidomide + dexamethasone) — current standard for transplant-eligible and many ineligible patients

— D-VRd (add daratumumab, anti-CD38) — emerging standard

— KRd (carfilzomib-based) — alternative

— Maintenance: lenalidomide post-transplant; reduces progression but increases secondary malignancy risk

— Bortezomib: peripheral neuropathy (give subcutaneously, weekly to reduce), herpes zoster reactivation → acyclovir prophylaxis required

— Lenalidomide: thromboembolism risk (give aspirin or anticoagulant prophylaxis); teratogen (REMS program); myelosuppression; secondary malignancies

— Carfilzomib: cardiotoxicity — heart failure, hypertension, pulmonary edema

— Daratumumab: infusion reactions; interferes with blood type cross-match (notify blood bank — daratumumab binds CD38 on RBCs causing false-positive indirect Coombs)

— Dexamethasone: hyperglycemia, insomnia, infection, GI bleeding, osteoporosis

— Bendamustine + rituximab or BTK inhibitors (ibrutinib, zanubrutinib — zanubrutinib preferred for less afib/HTN)

— Plasmapheresis for symptomatic hyperviscosity (urgent, before chemo)

— Daratumumab-CyBorD first-line

— Avoid lenalidomide in advanced cardiac amyloid (poor tolerance)

— Heart transplant or autoSCT in selected patients

— Zoledronic acid monthly or denosumab (preferred if CKD) — only when myeloma diagnosed

— Monitor for osteonecrosis of the jaw — dental exam before initiation

Key distinction: A patient with MGUS and osteoporosis still warrants standard osteoporosis dosing of bisphosphonates based on DXA/FRAX — but not the monthly myeloma dose. Don't confuse the two indications.

Because MGUS itself requires no drug, Step 3 questions probe drugs used in conditions on its differential or downstream.

Multiple myeloma — induction backbone:

Key toxicities to recognize on Step 3:

Waldenström macroglobulinemia:

AL amyloidosis specifics:

Bone-targeted therapy in myeloma (not MGUS):

Special Populations — Elderly and Renal/Hepatic Impairment

— Prevalence rises with age; ~7–8% over 85

— Competing risks: many will die with MGUS, not of it — life expectancy of <5 years from cardiovascular disease, dementia, or other comorbidity often outweighs progression risk

— Shared decision-making: in low-risk MGUS in a frail 90-year-old, annual surveillance may not change outcomes — reasonable to limit testing

— Avoid over-investigation: a low-risk MGUS in an 85-year-old with stable labs does not require bone marrow biopsy or whole-body MRI

— Critical distinction: is the renal dysfunction due to the clone (MGRS, light-chain cast nephropathy, AL amyloid, light-chain deposition disease, MIDD) or incidental (diabetic nephropathy, hypertensive nephrosclerosis, age-related decline)?

— Workup for any MGUS patient with renal disease:

— UPEP + urine IFE (Bence Jones)

— SFLC ratio (more sensitive than urine for light-chain disease)

— Albumin-to-total-protein ratio in urine (albuminuria predominant = glomerular/amyloid; light-chain predominant = tubular/cast)

— Low threshold for renal biopsy — diagnosis of MGRS upgrades observation to clone-directed therapy

— Drug dosing: if myeloma develops, lenalidomide requires renal dose adjustment; bortezomib does not

— Avoid IV iodinated contrast in patients with elevated light chains and AKI risk; gadolinium is acceptable if eGFR adequate

— Avoid NSAIDs

— Hepatic involvement is rare in pure MGUS; consider AL amyloidosis if hepatomegaly with elevated alkaline phosphatase out of proportion to bilirubin

— Bortezomib, dexamethasone require dose adjustment in significant hepatic dysfunction

Step 3 management: In an elderly patient with new CKD and an M-protein, the next step is SFLC ratio and urine studies — not simply attributing CKD to age. Missing MGRS is a high-stakes error because the renal disease is clone-driven and treatable.

Elderly patients (the modal MGUS patient):

Renal impairment:

Hepatic impairment:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— MGUS in pregnancy is rare (median age at diagnosis ~70); when it occurs, observation is appropriate

— Avoid radiation-based bone imaging; whole-body MRI without contrast is safe if imaging is indicated

— Neonatal effects of maternal M-protein are minimal; IgG crosses placenta but free light chains and IgM do not significantly

— If pregnancy occurs in a patient with prior MGUS, continue surveillance with serologic testing only

— MGUS in children/adolescents is vanishingly rare and should prompt evaluation for:

— Immunodeficiency (especially after stem cell transplant — post-transplant MGUS is common and usually transient)

— Chronic infection (HIV, EBV, hepatitis C)

— Autoimmune disease

— Always look for an underlying secondary cause in young patients

— 2–3× higher prevalence of MGUS and multiple myeloma

— Onset is earlier; M-protein patterns differ (more IgG, less IgM)

— Despite higher incidence, progression rates per year are similar — but cumulative lifetime risk is higher

— Some guidelines (and the iStopMM study data) support consideration of earlier screening in high-risk groups, though USPSTF does not currently recommend population screening

— ~2× increased risk

— No formal screening recommendation; evaluate if symptoms arise

— Higher prevalence of oligoclonal and monoclonal gammopathies, often transient

— Re-check after immune reconstitution before labeling as true MGUS

— Transient M-proteins common; usually resolve as immune system reconstitutes

— Persistent paraproteins require workup as in general population

Board pearl: A young adult with a new M-protein → don't reflexively call it MGUS. Order HIV, hepatitis B/C, EBV, and review for autoimmune disease and immunodeficiency before settling on the benign diagnosis.

Pregnancy:

Pediatrics:

Black patients:

First-degree relatives of MGUS/myeloma patients:

HIV/immunocompromised patients:

Post-solid organ or stem cell transplant:

Complications and Adverse Outcomes

— Non-IgM MGUS → multiple myeloma (most common), light-chain myeloma, AL amyloidosis, solitary plasmacytoma

— IgM MGUS → Waldenström macroglobulinemia, lymphoplasmacytic lymphoma, IgM myeloma (rare), other B-cell lymphomas

— Light-chain MGUS → light-chain myeloma, AL amyloidosis

— Risk ~1% per year, lifelong, non-diminishing — emphasize this to patients

— MGRS: renal disease from the monoclonal protein itself — AL amyloid, light-chain deposition disease, MIDD, cryoglobulinemic GN, C3 GN with paraprotein, light-chain proximal tubulopathy

— MGNS (neurologic significance): anti-MAG neuropathy, POEMS, chronic inflammatory demyelinating polyneuropathy variants

— MG-cutaneous significance: scleromyxedema, Schnitzler syndrome (IgM + urticaria + fever + bone pain), necrobiotic xanthogranuloma

— Cold agglutinin disease, type I cryoglobulinemia, acquired angioedema (acquired C1-inhibitor deficiency — IgM-related)

— Acquired von Willebrand syndrome with high M-protein

— MGUS independently associated with ~2× risk of osteoporosis and fragility fracture — screen with DXA

— Vertebral fractures may be misattributed to age — image any new back pain

— MGUS modestly increases venous thromboembolism risk (~2×); higher with IgM and IgA

— Threshold to evaluate unprovoked VTE in MGUS patients should be low

— Immunoparesis (suppressed uninvolved immunoglobulins) → increased risk of encapsulated organism infections

— Counsel on vaccinations and early evaluation of febrile illness

— "Premalignant" label causes anxiety; provide clear absolute risk numbers and reassurance

CCS pearl: In a CCS case of an MGUS patient who presents with new bone pain, AKI, hypercalcemia, or anemia, order CBC, calcium, creatinine, SPEP/IFE, SFLC, LDH, β2-microglobulin, and whole-body low-dose CT or MRI — and consult hematology. This is now a myeloma workup.

Progression to overt malignancy (the central concern):

Non-malignant clonal complications (MGCS — monoclonal gammopathy of clinical significance):

Bone health complications:

Thrombosis:

Infection:

Psychosocial:

When to Escalate — Consult, Inpatient, or Urgent Referral

— Any non-low-risk MGUS (IgA/IgM/IgD isotype, M-protein ≥1.5 g/dL, abnormal SFLC) at initial diagnosis for risk stratification and bone marrow planning

— Stable low-risk MGUS may be managed by primary care with annual labs

— Rising M-protein, new symptoms, or borderline labs → re-refer

— New CRAB feature or myeloma-defining event

— New peripheral neuropathy with IgM paraprotein

— Suspected AL amyloidosis (any sign — macroglossia, periorbital purpura, nephrotic syndrome, restrictive cardiomyopathy, autonomic neuropathy)

— Suspected MGRS (new proteinuria, AKI)

— New monoclonal cryoglobulinemia, cold agglutinin hemolysis, or acquired bleeding diathesis

— Hypercalcemia with symptoms or Ca >14 → IV fluids, calcitonin, bisphosphonate (denosumab if renal); avoid loop diuretics initially

— Acute kidney injury with elevated light chains → hydration, stop nephrotoxins, urgent heme consult; cast nephropathy may require bortezomib-based therapy ± plasma exchange in select cases

— Hyperviscosity syndrome (typically IgM): blurred vision, mucosal bleeding, neuro symptoms, retinal hemorrhage → emergent plasmapheresis, hematology consult

— Cord compression from plasmacytoma → MRI spine, neurosurgery/radiation oncology, IV dexamethasone

— Symptomatic anemia, pathologic fracture, severe infection

— Massive proteinuria with anasarca suspicious for amyloid → renal biopsy admission

— Nephrology: any renal involvement, biopsy planning

— Neurology: neuropathy workup, EMG/NCS, anti-MAG

— Cardiology: suspected cardiac amyloid (echo, cardiac MRI, NT-proBNP)

— Radiation oncology: solitary plasmacytoma

— Genetics/social work: familial clustering, financial toxicity of long surveillance

Step 3 management: A patient with known MGUS who presents to the ED with back pain and hypercalcemia is a myeloma until proven otherwise — admit, hydrate, treat hypercalcemia, image the spine, and get hematology on board the same day.

Outpatient referral to hematology (non-urgent but indicated):

Urgent outpatient/expedited referral (days to 1–2 weeks):

Inpatient admission / ED indications:

Specialty consults to consider:

Key Differentials — Other Plasma Cell and B-Cell Disorders

— M-protein ≥3 g/dL OR clonal marrow plasma cells 10–60%

— No CRAB, no myeloma-defining events

— Higher progression risk: ~10%/year first 5 years, then declines

— Surveillance every 3–6 months; clinical trials may offer early intervention for high-risk SMM (e.g., lenalidomide ± daratumumab)

— Clonal plasma cells ≥10% (or biopsy-proven plasmacytoma) plus at least one:

— CRAB: hypercalcemia (>11 or >1 above ULN), renal (Cr >2 or CrCl <40), anemia (Hgb <10 or >2 below normal), bone lesions (≥1 lytic lesion)

— SLiM: Sixty percent plasma cells, Light chain ratio ≥100 (involved/uninvolved), MRI >1 focal lesion

— Single bone or extramedullary mass; no systemic disease; treated with radiation; ~50% progress to myeloma over 10 years

— IgM paraprotein + ≥10% lymphoplasmacytic infiltrate in marrow + MYD88 L265P in >90%

— Hyperviscosity, lymphadenopathy, splenomegaly, anemia, neuropathy

— Clonal plasma cells produce misfolded light chains depositing in tissue

— Multisystem: cardiac (restrictive CM, low-voltage ECG with thick walls), renal (nephrotic), hepatic, GI, neuropathy, soft tissue (macroglossia)

— Diagnose with Congo red biopsy + mass spectrometry

Key distinction: MGUS → SMM → MM is a continuum defined by plasma cell burden and end-organ damage. The numbers you must memorize: MGUS <10% / <3 g/dL / no CRAB; SMM 10–60% or ≥3 g/dL / no CRAB; MM ≥10% + CRAB or myeloma-defining event.

Smoldering multiple myeloma (SMM):

Multiple myeloma:

Solitary plasmacytoma:

Waldenström macroglobulinemia:

AL amyloidosis:

Heavy chain disease (rare): γ, α, μ — IFE shows heavy chain without light chain

Lymphoplasmacytic lymphoma, marginal zone lymphoma, CLL with associated paraproteins — recognize when an M-protein appears alongside lymphadenopathy or cytopenias

Key Differentials — Non-Clonal Causes of an M-Spike or Elevated Globulins

— Chronic infection: HIV, hepatitis B/C, tuberculosis, endocarditis, osteomyelitis, parasitic infections

— Autoimmune disease: SLE, rheumatoid arthritis, Sjögren syndrome, IgG4-related disease, autoimmune hepatitis

— Chronic liver disease: cirrhosis (broad gamma, β-γ bridging on SPEP)

— Sarcoidosis

— Post-infectious (EBV, CMV, hepatitis)

— Post-vaccination

— Post-transplant (solid organ, allogeneic HSCT — often transient oligoclonal bands)

— Immune reconstitution states

— Action: repeat SPEP/IFE in 3–6 months; transient bands resolve

— Dehydration (raises all proteins proportionally; albumin also up)

— Chronic inflammation with elevated acute phase reactants

— Vitamin B12 or folate deficiency causing macrocytic anemia and neuropathy — easy to miss; check B12, MMA, folate before attributing neuropathy to MGUS

— Diabetic neuropathy vs. MGUS neuropathy — coexist often; EMG/NCS patterns and anti-MAG help distinguish

— CIDP vs. paraproteinemic neuropathy

— Renal amyloidosis (AL vs. AA vs. ATTR) — mass spectrometry typing is essential; AA is from chronic inflammation, ATTR is transthyretin-related (wild-type "senile" or hereditary), AL is clonal

— Cardiac amyloid: ATTR (especially in older men, Black patients with V122I variant) vs. AL — pyrophosphate scan distinguishes; don't miss ATTR — tafamidis is disease-modifying

— Osteoporotic fracture, metastatic carcinoma (breast, prostate, lung, kidney, thyroid), Paget disease, primary bone tumor

Board pearl: ATTR cardiac amyloidosis is not caused by MGUS, even though both can produce an M-protein and cardiac restrictive physiology. Always type the amyloid by mass spectrometry — treating an ATTR patient with myeloma chemotherapy is a critical error.

Polyclonal hypergammaglobulinemia (not MGUS — a broad-based hump on SPEP, not a sharp spike):

Reactive/transient monoclonal gammopathies:

Other causes of elevated total protein/gamma gap not from clonal disease:

Conditions mimicking MGUS clinically:

Bone pain differentials in older patients:

Long-Term Plan and Secondary Prevention

— Low-risk MGUS: SPEP, CBC, calcium, creatinine at 6 months → if stable, every 2–3 years or symptom-driven

— Intermediate/high-risk MGUS: SPEP, SFLC, CBC, CMP at 6 months → then annually for life

— Some experts continue lifelong annual labs even in low-risk patients; individualize based on life expectancy and patient preference

— DXA at diagnosis in patients with risk factors (postmenopausal women, men >70, glucocorticoid use, prior fracture)

— Treat osteoporosis per standard guidelines — bisphosphonates or denosumab; vitamin D ≥800 IU/day, calcium 1000–1200 mg/day total intake

— MGUS doubles fracture risk independent of other factors

— Vaccinations: annual influenza (inactivated), pneumococcal series, RSV (age-appropriate), zoster (Shingrix — non-live, safe), COVID-19, Tdap

— Patients with immunoparesis or recurrent infections may warrant IVIG replacement (specialist decision)

— Treat hypertension, dyslipidemia, diabetes per standard guidelines — not modified by MGUS

— MGUS is associated with increased VTE risk — do not routinely anticoagulate; do maintain low threshold for evaluation of VTE symptoms

— Tobacco cessation, moderate alcohol, regular weight-bearing exercise

— Maintain healthy weight (obesity is a myeloma risk factor)

— Avoid chronic NSAIDs (renal); use acetaminophen first-line for analgesia

— Caution with IV contrast if renal function borderline

— Notify blood bank of any anti-CD38 therapy if myeloma develops (daratumumab interferes with cross-match)

— Document MGUS in the problem list with risk category

— Communicate to all providers (especially before surgery, contrast studies, new meds)

— Provide patient with a wallet card or portal note summarizing diagnosis, last labs, and follow-up plan

Step 3 management: A patient with newly diagnosed low-risk MGUS asks "do I need chemo?" — the answer is no; the visit ends with DXA ordered, vaccinations updated, 6-month follow-up labs scheduled, and a clear symptom-return plan in writing.

Core long-term strategy: lifelong surveillance with no disease-directed therapy. Reinforce at each visit.

Surveillance cadence (re-stated for emphasis):

Bone health (high yield):

Infection prevention:

Cardiovascular risk:

Lifestyle counseling:

Medication safety:

Care coordination:

Follow-Up, Monitoring, and Counseling

— SPEP (quantify M-spike trend)

— CBC (anemia)

— CMP (calcium, creatinine)

— SFLC ratio (if non-IgG or abnormal at baseline)

— Quantitative immunoglobulins (immunoparesis)

— Targeted symptom review: bone pain, fatigue, neuropathy, B-symptoms, edema, paresthesias

— M-protein increase >25% AND ≥0.5 g/dL absolute

— New anemia, hypercalcemia, renal dysfunction

— New bone pain or pathologic fracture

— New neuropathy, organomegaly, or amyloid signs

— "You have a benign clone of plasma cells. There is about a 1% per year chance it could progress to multiple myeloma or a related disease. That risk doesn't go up over time, so even after 20 years you'd have roughly a 1 in 5 chance."

— "There is no medication that prevents progression. The best thing we can do is monitor."

— "Call the office if you develop new bone pain, unexplained fatigue, frequent infections, numbness/tingling in your feet, or unexplained weight loss."

— "Your immune system may be slightly weaker — please stay up to date on vaccines."

— Physical therapy for deconditioning, especially in elderly with falls/osteoporosis

— Occupational therapy if neuropathy compromises ADLs

— Pain management: acetaminophen, gabapentinoids for neuropathic pain, regional approaches before chronic opioids

— Address the "cancer-adjacent" anxiety — many patients catastrophize the label

— Refer to social work or behavioral health for distress

— Patient education resources: International Myeloma Foundation, LLS

— When primary care provider changes, ensure the MGUS problem list entry transfers

— On hospital discharge after any unrelated admission, confirm MGUS surveillance is not lost in handoff

CCS pearl: On a CCS case, after stabilizing acute issues, always order the next follow-up appointment with specific lab orders attached — failing to schedule the 6-month MGUS recheck is a common scoring miss.

What to recheck at each follow-up visit:

Triggers to repeat imaging / bone marrow:

Counseling points — script for the visit:

Rehab and supportive care:

Psychosocial support:

Transitions of care:

Ethical, Legal, and Patient Safety Considerations

— Patients must understand that MGUS is premalignant, that surveillance does not prevent progression, and that the goal is early detection of complications

— Some patients prefer not to know — respect autonomy, but document the discussion

— Disclose absolute risk (1%/year) rather than relative risk to avoid catastrophizing

— Do not order bone marrow biopsy or whole-body MRI on low-risk MGUS without indication — causes harm, anxiety, and cost

— Do not prescribe myeloma chemotherapy for MGUS — exposes patients to serious adverse effects without benefit

— Do not label transient post-infectious or post-transplant M-proteins as MGUS prematurely — repeat in 3–6 months first

— Transitions of care: MGUS diagnosed during hospitalization for another reason must be communicated to the outpatient PCP with a clear follow-up plan; failure to do so is a sentinel "missed handoff" scenario

— Pathologic fracture risk: avoid aggressive PT in patients with new bone pain until imaging excludes lytic lesion

— Blood bank notification: if anti-CD38 therapy is started (after progression to myeloma), notify blood bank to avoid transfusion delays

— Contrast safety: identify patients with elevated light chains and CKD before IV iodinated contrast; consider alternative imaging

— Medication reconciliation: stop NSAIDs and other nephrotoxins; review for drug-drug interactions when therapy begins

— An MGUS diagnosis may affect life insurance underwriting — patients should be counseled before obtaining the diagnosis if they are mid-application; this is a legitimate disclosure issue

— Long-term surveillance costs and prior-authorization burdens — discuss value-based testing intervals

— MGUS is not reportable to cancer registries (premalignant)

— Progression to myeloma, Waldenström, or amyloidosis triggers cancer registry reporting

— Population screening for MGUS is not currently recommended by USPSTF; iStopMM and PROMISE trials are evaluating

— Avoid opportunistic screening that creates anxiety without benefit

Board pearl: A vignette where a patient with newly diagnosed MGUS asks if they need to inform their employer or stop working — the answer is no; MGUS is not disabling, not contagious, and does not affect work capacity.

Informed consent for surveillance:

Avoiding overdiagnosis and overtreatment:

Patient safety — high-yield Step 3 items:

Insurance and life-insurance implications:

Mandatory reporting and registries:

Research and screening ethics:

High-Yield Associations and Rapid-Fire Facts

— MGUS prevalence: 3% over 50, 5% over 70

— Progression rate: ~1%/year, lifelong, non-diminishing

— MGUS criteria: M-protein <3 g/dL, marrow plasma cells <10%, no CRAB

— SMM: ≥3 g/dL OR 10–60% plasma cells, no CRAB; progression ~10%/yr first 5 yrs

— SFLC ratio normal range: 0.26–1.65

— Myeloma-defining FLC ratio: involved/uninvolved ≥100 with involved FLC ≥100 mg/L

— M-protein ≥1.5 g/dL

— Non-IgG isotype

— Abnormal SFLC ratio

— IgG/IgA → multiple myeloma

— IgM → Waldenström macroglobulinemia

— Light chain → light-chain myeloma or AL amyloidosis

— Rouleaux on smear → paraproteinemia

— Macroglossia + periorbital purpura → AL amyloidosis

— Low-voltage ECG + thick-walled heart on echo → cardiac amyloidosis (discordance sign)

— MYD88 L265P mutation → Waldenström macroglobulinemia

— Hyperviscosity (blurred vision, epistaxis, neuro symptoms) → IgM Waldenström

— Anti-MAG antibody → IgM-associated peripheral neuropathy

— POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, M-protein (usually λ), Skin changes; elevated VEGF

— Schnitzler syndrome: IgM + chronic urticaria + fever + bone pain

— Acquired C1-inhibitor deficiency with angioedema → underlying B-cell clone

— Cold agglutinin disease → IgM-κ usually

Key distinction: Always distinguish AL (treat clone) from ATTR (tafamidis, not chemo) amyloidosis by mass spectrometry — clinical and echo features overlap.

Numbers to memorize:

Mayo risk factors (memorize the 3):

Isotype → progression target:

Classic associations:

Imaging: plain skeletal survey is obsolete; use whole-body low-dose CT, MRI, or PET/CT

Vaccine list: flu, pneumococcal, RSV, zoster (Shingrix — non-live), COVID-19, Tdap

Daratumumab interferes with cross-match (binds CD38 on RBCs) — notify blood bank

Bortezomib → herpes zoster reactivation → acyclovir prophylaxis

Carfilzomib → cardiotoxicity; lenalidomide → VTE and teratogenicity

Board Question Stem Patterns

— "A 68-year-old man has routine labs showing total protein 8.2, albumin 4.0. He is asymptomatic. SPEP shows IgG-κ M-spike of 1.2 g/dL. CBC, calcium, creatinine are normal. What is the next step?"

— Answer: SFLC ratio, urine studies; if all normal and low-risk → observation with repeat labs in 6 months (no bone marrow, no imaging)

— "M-protein is IgA at 1.8 g/dL with abnormal SFLC ratio."

— Answer: This is not low risk — bone marrow biopsy + whole-body imaging

— Known MGUS patient develops back pain, hypercalcemia, anemia, AKI

— Answer: Diagnose myeloma — admit, hydrate, treat hypercalcemia, image spine, heme consult, start dexamethasone if cord compression

— "Patient with known MGUS develops nephrotic syndrome / macroglossia / restrictive cardiomyopathy."

— Answer: Fat pad / affected-organ biopsy with Congo red + mass spectrometry; refer for AL amyloid therapy

— IgM patient with blurred vision, mucosal bleeding, headache, retinal hemorrhages

— Answer: Emergent plasmapheresis before chemotherapy; hematology consult

— Older patient with distal sensory neuropathy and IgM-κ paraprotein

— Answer: Check anti-MAG antibody; symptomatic care; rituximab if severe

— MGUS patient with new proteinuria and AKI

— Answer: Renal biopsy — observation alone is wrong; clone-directed therapy may be needed even without myeloma criteria

— Stable MGUS, patient asks for "preventive chemo"

— Answer: Reassurance, continued surveillance, no therapy

— Young patient post-EBV or post-transplant with M-spike

— Answer: Repeat in 3–6 months before labeling MGUS; rule out HIV, hepatitis, autoimmune

— MGUS patient asking about zoster vaccine

— Answer: Shingrix (recombinant, non-live) is appropriate and indicated

Step 3 management: When the stem ends "what is the most appropriate next step?" the answer in stable, asymptomatic MGUS is almost always schedule follow-up labs — not biopsy, not imaging, not therapy.

Stem pattern 1 — The incidental M-spike:

Stem pattern 2 — When to biopsy the marrow:

Stem pattern 3 — Progression to myeloma:

Stem pattern 4 — Amyloidosis recognition:

Stem pattern 5 — Hyperviscosity:

Stem pattern 6 — Neuropathy workup:

Stem pattern 7 — MGRS:

Stem pattern 8 — Don't over-treat:

Stem pattern 9 — Transient M-protein:

Stem pattern 10 — Vaccine question:

One-Line Recap

MGUS is an asymptomatic premalignant plasma cell disorder defined by M-protein <3 g/dL, clonal marrow plasma cells <10%, and absence of CRAB or myeloma-defining events, managed with risk-stratified lifelong surveillance — never with disease-directed therapy.

— Always confirm with SPEP + IFE + SFLC + UPEP/urine IFE, and exclude end-organ damage with CBC, calcium, creatinine before applying the MGUS label

— A gamma gap >4 g/dL is your cheapest screening trigger

— M-protein ≥1.5 g/dL, non-IgG isotype, abnormal SFLC ratio

— Low risk (0 factors): observation, 6-month then 2–3 year intervals, no marrow, no imaging

— Intermediate/high risk: bone marrow biopsy + whole-body low-dose CT/MRI at baseline, annual surveillance for life

— SMM (≥3 g/dL or 10–60% marrow plasma cells, no CRAB; ~10%/yr progression)

— Multiple myeloma (CRAB or SLiM criteria)

— Waldenström (IgM + lymphoplasmacytic + MYD88 L265P)

— AL amyloidosis (macroglossia, nephrotic syndrome, cardiac, neuropathy — Congo red + mass spec)

— MGRS (clone-driven renal disease — biopsy and treat the clone even without myeloma)

— Never start chemotherapy for MGUS

— Always schedule the 6-month follow-up labs at the index visit

— Vaccinate, optimize bone health with DXA, avoid nephrotoxins

— Counsel clearly: 1%/year progression risk, symptom-driven return

— Communicate the diagnosis across transitions of care to prevent loss of surveillance

Board pearl: Master the numbers — <3 g/dL, <10%, no CRAB, 1%/year, 3 risk factors — and the vast majority of MGUS Step 3 questions become pattern recognition.

Diagnostic core:

Risk stratification (Mayo, 3 factors):

Recognize the dangerous neighbors:

Step 3 daily-practice essentials: